Gesine Bug - Concepedia

Author

Gesine Bug

Goethe University Frankfurt ORCID

Also Known As

Bug, Gesine, G Bug, G. Bug, GESINE BUG, Gesine Bug, K Götze

365

Publications

9.6K

Citations

H-Index

101

Concepts

All Affiliations

Goethe University Frankfurt University Hospital Frankfurt Heidelberg University Medizinische Hochschule Hannover University Hospital Heidelberg

About

Gesine Bug is an author at Goethe University Frankfurt specializing in medicine, hematology, and cell transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	48	3.5K
2	Health Sciences	18	19	1K
3	Blood Transplantation	11	11	1.1K
4	Public Health	1	1	32
5	Biomedical Engineering	1	1	65

Gesine Bug

121

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>–Internal Tandem Duplication Mutation (SORMAIN) Andreas Burchert, Gesine Bug, Lea Fritz, Journal of Clinical Oncology	2020	538
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey Robert Zeiser, Andreas Burchert, Claudia Lengerke, Leukemia TransplantationStem Cell TransplantationTransplantation MedicineImmunologyStem Cell Research	2015	535
Treatment of patients with advanced cancer with the natural killer cell line NK-92 Torsten Tonn, Dirk Schwabe, Hans Klingemann, Cytotherapy Lymphoid NeoplasiaAdvanced CancerCell TherapyCancer ImmunosurveillanceMedicine	2013	461
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes Felicitas Thol, Sofia Kade, Carola Schlarmann, Blood	2012	417
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, The Lancet Oncology Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyClinical Trials	2018	341
Prognostic Significance of<i>ASXL1</i>Mutations in Patients With Myelodysplastic Syndromes Felicitas Thol, Inna Friesen, Frédérik Damm, Journal of Clinical Oncology	2011	274
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation Thomas Schroeder, Akos Czibere, Uwe Platzbecker, Leukemia Cell TherapyTransplantationMarrow TransplantationFirst Salvage TherapyStem Cell Transplantation	2013	220
<scp>CD</scp>19‐<scp>CAR</scp> engineered <scp>NK</scp>‐92 cells are sufficient to overcome <scp>NK</scp> cell resistance in B‐cell malignancies A Romański, Christoph Uherek, Gesine Bug, Journal of Cellular and Molecular Medicine	2016	220
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Michael Stadler, Martin Bornhäuser, Gesine Bug, Blood	2005	199
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group Thomas Schroeder, Elena Rachlis, Gesine Bug, Biology of Blood and Marrow Transplantation	2014	198

Page 1